319 related articles for article (PubMed ID: 19753537)
41. β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.
Gatto F; Feelders R; van der Pas R; Kros JM; Dogan F; van Koetsveld PM; van der Lelij AJ; Neggers SJ; Minuto F; de Herder W; Lamberts SW; Ferone D; Hofland LJ
Endocrinology; 2013 Dec; 154(12):4715-25. PubMed ID: 24169548
[TBL] [Abstract][Full Text] [Related]
42. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
43. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
[TBL] [Abstract][Full Text] [Related]
44. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.
Casar-Borota O; Heck A; Schulz S; Nesland JM; Ramm-Pettersen J; Lekva T; Alafuzoff I; Bollerslev J
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1730-9. PubMed ID: 24092823
[TBL] [Abstract][Full Text] [Related]
45. Somatostatin receptors in GH-secreting pituitary adenomas--their relationship to the response to octreotide.
Pawlikowski M; Pisarek H; Kunert-Radek J; Radek M
Endokrynol Pol; 2008; 59(3):196-9. PubMed ID: 18615392
[TBL] [Abstract][Full Text] [Related]
46. Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
Saveanu A; Gunz G; Dufour H; Enjalbert A; Culler MD; Jaquet P
J Endocrinol Invest; 2003; 26(8 Suppl):4-7. PubMed ID: 15233203
[No Abstract] [Full Text] [Related]
47. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
Taboada GF; Neto LV; Luque RM; Córdoba-Chacón J; de Oliveira Machado E; de Carvalho DP; Kineman RD; Gadelha MR
Neuroendocrinology; 2011; 93(1):40-7. PubMed ID: 21079388
[TBL] [Abstract][Full Text] [Related]
48. Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas.
Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Astrup J; Weeke J; Jørgensen JO
J Clin Endocrinol Metab; 1998 Aug; 83(8):2997-3000. PubMed ID: 9709982
[TBL] [Abstract][Full Text] [Related]
49. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
50. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
51. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
[TBL] [Abstract][Full Text] [Related]
52. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
Gatto F; Barbieri F; Castelletti L; Arvigo M; Pattarozzi A; Annunziata F; Saveanu A; Minuto F; Castellan L; Zona G; Florio T; Ferone D
Pituitary; 2011 Jun; 14(2):141-7. PubMed ID: 21086053
[TBL] [Abstract][Full Text] [Related]
53. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
Venegas-Moreno E; Vazquez-Borrego MC; Dios E; Gros-Herguido N; Flores-Martinez A; Rivero-Cortés E; Madrazo-Atutxa A; Japón MA; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
J Cell Mol Med; 2018 Mar; 22(3):1640-1649. PubMed ID: 29266696
[TBL] [Abstract][Full Text] [Related]
54. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
55. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
[TBL] [Abstract][Full Text] [Related]
56. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
Shimon I
Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
[TBL] [Abstract][Full Text] [Related]
57. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
Cuevas-Ramos D; Fleseriu M
J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
[TBL] [Abstract][Full Text] [Related]
58. Varying additive effects of bromocriptine with two somatostatin analogs in cultures of GH-secreting adenomas.
Balsa JA; Varela C; Lucas T; García-Uría J; Barceló B; Sancho-Rof JM
Horm Metab Res; 2002 Aug; 34(8):435-40. PubMed ID: 12198598
[TBL] [Abstract][Full Text] [Related]
59. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
60. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Rass L; Rahvar AH; Matschke J; Saeger W; Renné T; Aberle J; Flitsch J; Rotermund R
Hormones (Athens); 2022 Mar; 21(1):79-89. PubMed ID: 34674191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]